FindTrial
Sign In

Development of an Intelligent Diagnosis Model for Precise Mangement of locally advanced rectal cancer based on the transcriptome signature

Constructing the combined predictive model of tumor lymphatic metastasis and complete response to total neoadjuvant therapy in locally advanced rectal cancer based on the transcriptome signature

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038957
Enrollment
Unknown
Registered
2020-10-10
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

Gold Standard:Pathological results
Index test:Intelligent&#32
diagnosis&#32
model&#32
for&#32
precise&#32
mangement&#32
of&#32
locally&#32
advanced&#32
rectal&#32
cancer&#32
based&#32
on&#32
the&#32
tran&#115
criptome&#32
signature.

Sponsors

First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: MRI or pathological examination showed that the primary tumor invaded the base of the intestinal wall until lymph node metastasis appeared in the surrounding structures or mesangial membrane and within the pelvic area, without distal metastasis, and within 12cm from the anus.

Exclusion criteria

Exclusion criteria: Patients with other tumor lesions, or with indications for emergency surgery, or with familial polyposis cancerosis or Lynch syndrome in last 5 years.

Design outcomes

Primary

MeasureTime frame
score of the transcriptome signature;—

Countries

China

Contacts

Public ContactGuo You

The First Affiliated Hospital of Gannan Medical University

gy@gmu.edu.cn+86 19979711221

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026